Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Kennedy scientists join world-leading researchers in ‘pivotal’ study to help arthritis patients to live drug free

The prospect of long-lasting drug-free remission for children and adults living with inflammatory arthritis is a step closer to becoming a reality, thanks to a new collaboration.

Rapamycin helps protect immune cells against DNA damage

New research carried out by Dr Loren Kell at the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) has demonstrated for the first time that rapamycin can reduce DNA damage in immune cells, a hallmark of ageing.

Rewiring T cell co-receptors to improve the safety of cancer immunotherapy

A new study from the Dushek and van der Merwe labs demonstrates a novel strategy to reduce dangerous off-target effects in engineered T cell therapies.

What determines the fate of a T cell?

Research led by Dr Mariana Borsa at the Kennedy Institute has found that a cellular housekeeping mechanism called autophagy plays a major role in ensuring that T cells generate diverse progenies upon cell division. The findings, published in Nature Cell Biology, could help boost vaccine response in older adults.

Kennedy researchers contribute to UK-wide AI and bioscience training initiative

Together with a group of Oxford researchers, Mark Coles, Professor of Immunology at the Kennedy Institute, will co-lead the Enabling Next-generation AI for a Bioscience-Led Economy (ENAIBLE) initiative.

Blood test predicts risk of death in acutely ill children in lower-income countries

An international study has identified a blood-based indicator of intestinal damage and inflammation that strongly predicts mortality in sick children. The new biomarker could help to identify those children at greatest risk of dying after hospitalisation in parts of the world with limited resources.

Professor Sarah Blagden shares cutting-edge precision prevention research at Oxford in new Channel 4 Documentary

Over the past year, Professor Blagden has been filming for Cancer Detectives: Finding the Cures, a new three-part documentary series from Channel 4 which follows three scientists on the front lines of cancer research across the UK.

Oxford and GSK launch Experimental Medicine Collaboration

GSK invests £10 million over five years to establish the Experimental Medicine Collaboration with the University of Oxford.

World’s first lung cancer prevention vaccine gets £2 million for clinical trial

People at high risk of lung cancer will soon be able to receive the first-ever experimental vaccine, 'LungVax', designed to prevent the disease, in a world-first clinical trial. The LungVax vaccine carries a series of genetic instructions which train the immune system to recognise tumour antigens on the surface of abnormal lung cells.

Shaping immunity - the secrets behind the shape of neutrophils

Researchers at the Kennedy Institute have provided the most comprehensive overview to date of how the distinctive segmented nucleus of neutrophils influences their function in health and disease.

Oxford researchers to redefine new human-based research models of pain

Professor Tonia Vincent is part of an interdisciplinary team from Oxford University leading a major new initiative which aims to redefine human-based research models for greater understanding of disease and the acceleration of new medicines.

Oxford scientists map the cells that drive Crohn’s disease fistulas

Researchers at the MRC Translational Immune Discovery Unit have identified how rare populations of abnormal cells drive the formation and persistence of fistulas - painful, tunnel-like tracts that develop in around 30% of people with Crohn’s disease - paving the way for targeted treatments.

Dr Ignacio Melero recognised for global contribution to advances in cancer immunotherapy

The Society for Immunotherapy of Cancer (SITC) has honoured Dr Ignacio (Nacho) Melero, Professor of Immunotherapy at NDM's Centre for Immuno-Oncology at Oxford, for his pioneering research transforming cancer treatment through immunotherapy.

Oxford scientists capture genome’s structure in unprecedented detail

Radcliff Department of Medicine scientists have achieved the most detailed view yet of how DNA folds and functions inside living cells, revealing the physical structures that control when and how genes are switched on.

New Microbiome Innovation Network to drive UK Bioscience Research

Researchers from the Kennedy Institute are part of a UK-wide consortium that has been awarded a £644K BBSRC Network Grant to establish the Microbiome Innovation Network (Microbiome-Net).

Oxford Oncology at ESMO 2025

Members of the Department of Oncology attended ESMO earlier this month to present their research, chair sessions, and network with collaborators from across Europe and beyond. Read the highlights from our department’s contributions to ESMO 2025.

Podcast: Regulatory T cell therapy in kidney transplants

A conversation with Fadi Issa about his recent article on regulatory T cell therapy in kidney transplants.

Major investment puts UK universities at the forefront of groundbreaking lymph node research

Three UK universities have been granted over £1.7m by the Medical Research Council (MRC) to establish a network of lymph node research centres across the UK. The novel LEGACY IIII Network (Lymph nodE single cell Genomics AnCestrY immunity, infection, inflammation and immunisation) will be co-led by the Universities of Oxford, Cardiff and Newcastle and will establish ten specialist lymph node research centres across the country.

Load More